» Articles » PMID: 23966418

Alpha-synuclein Post-translational Modifications As Potential Biomarkers for Parkinson Disease and Other Synucleinopathies

Overview
Date 2013 Aug 23
PMID 23966418
Citations 101
Authors
Affiliations
Soon will be listed here.
Abstract

The development of novel therapies against neurodegenerative disorders requires the ability to detect their early, presymptomatic manifestations in order to enable treatment before irreversible cellular damage occurs. Precocious signs indicative of neurodegeneration include characteristic changes in certain protein levels, which can be used as diagnostic biomarkers when they can be detected in fluids such as blood plasma or cerebrospinal fluid. In the case of synucleinopathies, cerebrospinal alpha-synuclein (α-syn) has attracted great interest as a potential biomarker; however, there is ongoing debate regarding the association between cerebrospinal α-syn levels and neurodegeneration in Parkinson disease and synucleinopathies. Post-translational modifications (PTMs) have emerged as important determinants of α-syn's physiological and pathological functions. Several PTMs are enriched within Lewy bodies and exist at higher levels in α-synucleinopathy brains, suggesting that certain modified forms of α-syn might be more relevant biomarkers than the total α-syn levels. However, the quantification of PTMs in bodily fluids poses several challenges. This review describes the limitations of current immunoassay-based α-syn quantification methods and highlights how these limitations can be overcome using novel mass-spectrometry-based assays. In addition, we describe how advances in chemical synthesis, which have enabled the preparation of α-syn proteins that are site-specifically modified at single or multiple residues, can facilitate the development of more accurate assays for detecting and quantifying α-syn PTMs in health and disease.

Citing Articles

Accumulation of alpha-synuclein pathology in the liver exhibits post-translational modifications associated with Parkinson's disease.

Hallbeck M, Ekmark-Lewen S, Kahle P, Ingelsson M, Reyes J iScience. 2024; 27(12):111448.

PMID: 39720536 PMC: 11667178. DOI: 10.1016/j.isci.2024.111448.


Analysis and comparison of post-translational modifications of α-synuclein filaments in multiple system atrophy and dementia with Lewy bodies.

Kametani F, Tahira M, Takao M, Matsubara T, Hasegawa K, Yoshida M Sci Rep. 2024; 14(1):22892.

PMID: 39358446 PMC: 11446954. DOI: 10.1038/s41598-024-74130-z.


Folding of N-terminally acetylated α-synuclein upon interaction with lipid membranes.

Tang Z, Fang Z, Wu X, Liu J, Tian L, Li X Biophys J. 2024; 123(21):3698-3720.

PMID: 39306670 PMC: 11560312. DOI: 10.1016/j.bpj.2024.09.019.


Posttranslational Modifications of -Synuclein, Their Therapeutic Potential, and Crosstalk in Health and Neurodegenerative Diseases.

Hassanzadeh K, Liu J, Maddila S, Mouradian M Pharmacol Rev. 2024; 76(6):1254-1290.

PMID: 39164116 PMC: 11549938. DOI: 10.1124/pharmrev.123.001111.


O-GlcNAc Modification of α-Synuclein Can Alter Monomer Dynamics to Control Aggregation Kinetics.

Gamage K, Wang B, Hard E, Van T, Galesic A, Phillips G ACS Chem Neurosci. 2024; 15(16):3044-3052.

PMID: 39082221 PMC: 11342298. DOI: 10.1021/acschemneuro.4c00301.


References
1.
Olsen J, Macek B, Lange O, Makarov A, Horning S, Mann M . Higher-energy C-trap dissociation for peptide modification analysis. Nat Methods. 2007; 4(9):709-12. DOI: 10.1038/nmeth1060. View

2.
Addona T, Abbatiello S, Schilling B, Skates S, Mani D, Bunk D . Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol. 2009; 27(7):633-41. PMC: 2855883. DOI: 10.1038/nbt.1546. View

3.
Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A . Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276(5321):2045-7. DOI: 10.1126/science.276.5321.2045. View

4.
Danielson S, Held J, Schilling B, Oo M, Gibson B, Andersen J . Preferentially increased nitration of alpha-synuclein at tyrosine-39 in a cellular oxidative model of Parkinson's disease. Anal Chem. 2009; 81(18):7823-8. PMC: 2748813. DOI: 10.1021/ac901176t. View

5.
Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg M . alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002; 4(2):160-4. DOI: 10.1038/ncb748. View